Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Darzalex (daratumumab) - Important Safety Information from Janssen Ireland as approved by HPRA
Notice type:
3rd Party Publications
Date:
27/06/2019
Problem Or Issue:
Important Safety Information communication from Janssen Ireland on DARZALEX (daratumumab) and risk of reactivation of hepatitis B virus: Hepatitis B virus status to be established in patients receiving DARZALEX
Important Safety Information - Darzalex (daratumumab)
« Back
Date Printed: 23/04/2024